Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4481 Comments
820 Likes
1
Mostyn
Active Contributor
2 hours ago
Expert US stock short interest and short squeeze potential analysis for identifying high-risk high-reward opportunities. Our short interest data helps you understand bearish sentiment and potential catalysts for short covering rallies.
👍 11
Reply
2
Mealea
Senior Contributor
5 hours ago
Broad participation indicates a stable market environment.
👍 210
Reply
3
Terri
Elite Member
1 day ago
Too late to act… sigh.
👍 250
Reply
4
Keirrah
Active Contributor
1 day ago
That made me do a double-take. 👀
👍 123
Reply
5
Majed
Experienced Member
2 days ago
Who else is thinking “what is going on”?
👍 194
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.